Skip to main content
FinSpry Logo
FinSpry
CBIO logo
CBIO
(NASDAQ)
Gyre Therapeutics, Inc.
$19.40-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Gyre Therapeutics (CBIO) Stock Price & Financial Analysis

Gyre Therapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$18.38 - $20.10
52-Week High$29.00
52-Week Low$8.72
Open$19.00
Volume209.00K
Average Volume (3M)209.00K
Market Cap2.02B
Shares Outstanding104.14M
Price to Sales (P/S)48.59
Price to Book (P/B)9.91
EV/EBITDA-12.20
Revenue (TTM)41.41M
Net Income (TTM)-141.14M
Free Cash Flow (TTM)-23.40M
EPS (TTM)$-1.36
Profit Margin-340.85%
Operating Margin-340.05%
Return on Equity (ROE)-69.52%
Debt to Equity0.01
50-Day MA$11.58
200-Day MA$12.70
52-Week Change-3.40%
Annual Dividend$0.00
Dividend Yield0.00%
Last Dividend Ex-DateJan 13, 2023

Frequently Asked Questions About Gyre Therapeutics

What is the current stock price for CBIO?

As of the latest trading session, CBIO stock trades at $19.40. The 52-week range is $8.72–$29.00, with a day range of $18.38–$20.10.

What is the P/E ratio for CBIO?

The P/E ratio (Price-to-Earnings) for CBIO is shown in the Key Statistics section. This valuation metric helps compare Gyre Therapeutics, Inc. to industry peers.

Does CBIO pay dividends?

Gyre Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for CBIO?

Based on 2 analysts, the consensus for CBIO is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of CBIO?

Gyre Therapeutics's market capitalization is $2.02B, classifying it as a mid-cap company. Gyre Therapeutics operates in the Healthcare sector within the Biotechnology industry.